

Manju A Kurian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8870485/publications.pdf>

Version: 2024-02-01

73
papers

4,456
citations

126907

33
h-index

118850

62
g-index

75
all docs

75
docs citations

75
times ranked

8431
citing authors

#	ARTICLE	IF	CITATIONS
1	Biallelic <i>AOPEP</i> Loss-of-Function Variants Cause Progressive Dystonia with Prominent Limb Involvement. <i>Movement Disorders</i> , 2022, 37, 137-147.	3.9	14
2	The dopamine transporter gene <i>SLC6A3</i> : multidisease risks. <i>Molecular Psychiatry</i> , 2022, 27, 1031-1046.	7.9	28
3	Structural mapping of <i>GABRB3</i> variants reveals genotype-phenotype correlations. <i>Genetics in Medicine</i> , 2022, 24, 681-693.	2.4	10
4	Relationship of Genotype, Phenotype, and Treatment in Dopa-Responsive Dystonia: <i>MDSGene</i> Review. <i>Movement Disorders</i> , 2022, 37, 237-252.	3.9	19
5	Comparison of methylation epigenatures in <i>KMT2B</i> - and <i>KMT2D</i> -related human disorders. <i>Epigenomics</i> , 2022, 14, 537-547.	2.1	10
6	Highlighting the Dystonic Phenotype Related to <i>GNAO1</i> . <i>Movement Disorders</i> , 2022, 37, 1547-1554.	3.9	25
7	<i>STXBP1</i> Stop-Loss Mutation Associated with Complex Early Onset Movement Disorder without Epilepsy. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 837-840.	1.5	3
8	Freezing of Gait as a Complication of Pallidal Deep Brain Stimulation in <i>DYT1-KMT2B</i> Patients with Evidence of Striatonigral Degeneration. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 992-996.	1.5	1
9	Precision medicine for genetic childhood movement disorders. <i>Developmental Medicine and Child Neurology</i> , 2021, 63, 925-933.	2.1	4
10	Aromatic <i>l</i> -amino acid decarboxylase deficiency: a patient-derived neuronal model for precision therapies. <i>Brain</i> , 2021, 144, 2443-2456.	7.6	16
11	A Recurrent <i>VPS16</i> p.Arg187* Nonsense Variant in Early-Onset Generalized Dystonia. <i>Movement Disorders</i> , 2021, 36, 1984-1985.	3.9	7
12	An Update on the Phenotype, Genotype and Neurobiology of <i>ADCY5</i> -Related Disease. <i>Movement Disorders</i> , 2021, 36, 1104-1114.	3.9	24
13	Childhood-Onset Chorea Caused by a Recurrent De Novo <i>DRD2</i> Variant. <i>Movement Disorders</i> , 2021, 36, 1472-1473.	3.9	6
14	Assessment of intellectual impairment, health-related quality of life, and behavioral phenotype in patients with neurotransmitter related disorders: Data from the <i>iNTD</i> registry. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 1489-1502.	3.6	7
15	Commentary: Galactosemia Diagnosis by Whole Exome Sequencing Later in Life. <i>Movement Disorders Clinical Practice</i> , 2021, 8, S40-S41.	1.5	0
16	Commentary: <i>GM1</i> -Gangliosidosis Type III Associated Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2021, 8, S24-S25.	1.5	0
17	Consensus clinical management guideline for beta-propeller protein-associated neurodegeneration. <i>Developmental Medicine and Child Neurology</i> , 2021, 63, 1402-1409.	2.1	17
18	Enhanced cGAS-STING-dependent interferon signaling associated with mutations in <i>ATAD3A</i> . <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	43

#	ARTICLE	IF	CITATIONS
19	TNPO2 variants associate with human developmental delays, neurologic deficits, and dysmorphic features and alter TNPO2 activity in Drosophila. American Journal of Human Genetics, 2021, 108, 1669-1691.	6.2	23
20	Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines. Nature Communications, 2021, 12, 5529.	12.8	21
21	<i>RHOBTB2</i> Mutations Expand the Phenotypic Spectrum of Alternating Hemiplegia of Childhood. Neurology, 2021, 96, e1539-e1550.	1.1	15
22	The role of manganese dysregulation in neurological disease: emerging evidence. Lancet Neurology, The, 2021, 20, 956-968.	10.2	51
23	Towards Precision Therapies for Inherited Disorders of Neurodegeneration with Brain Iron Accumulation. Tremor and Other Hyperkinetic Movements, 2021, 11, 51.	2.0	7
24	Biallelic Mutations of <i>TBC1D24</i> in Exercise-Induced Paroxysmal Dystonia. Movement Disorders, 2020, 35, 372-373.	3.9	8
25	The expanding spectrum of movement disorders in genetic epilepsies. Developmental Medicine and Child Neurology, 2020, 62, 178-191.	2.1	31
26	Recent genetic advances in early-onset dystonia. Current Opinion in Neurology, 2020, 33, 500-507.	3.6	5
27	Loss-of-Function Variants in <i>HOPS</i> Complex Genes <i>VPS16</i> and <i>VPS41</i> Cause Early Onset Dystonia Associated with Lysosomal Abnormalities. Annals of Neurology, 2020, 88, 867-877.	5.3	70
28	<i>KMT2B</i> -related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation. Brain, 2020, 143, 3242-3261.	7.6	57
29	<i>AADC</i> deficiency from infancy to adulthood: Symptoms and developmental outcome in an international cohort of 63 patients. Journal of Inherited Metabolic Disease, 2020, 43, 1121-1130.	3.6	59
30	<i>DNAJC6</i> Mutations Disrupt Dopamine Homeostasis in Juvenile <i>Parkinsonism-Dystonia</i> . Movement Disorders, 2020, 35, 1357-1368.	3.9	22
31	<i>KIF1A</i> -related disorders in children: A wide spectrum of central and peripheral nervous system involvement. Journal of the Peripheral Nervous System, 2020, 25, 117-124.	3.1	40
32	Autosomal dominant mitochondrial membrane protein-associated neurodegeneration (MPAN). Molecular Genetics & Genomic Medicine, 2019, 7, e00736.	1.2	40
33	Frequency and phenotypic spectrum of <i>KMT2B</i> dystonia in childhood: A single-center cohort study. Movement Disorders, 2019, 34, 1516-1527.	3.9	55
34	Bi-allelic Loss-of-Function CACNA1B Mutations in Progressive Epilepsy-Dyskinesia. American Journal of Human Genetics, 2019, 104, 948-956.	6.2	45
35	Yield of comparative genomic hybridization microarray in pediatric neurology practice. Neurology: Genetics, 2019, 5, e367.	1.9	4
36	Phenotypes, genotypes, and the management of paroxysmal movement disorders. Developmental Medicine and Child Neurology, 2018, 60, 559-565.	2.1	31

#	ARTICLE	IF	CITATIONS
37	Neurodegeneration with brain iron accumulation. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 147, 293-305.	1.8	153
38	Clinical and molecular characterization of <i>KCNT1</i> -related severe early-onset epilepsy. Neurology, 2018, 90, e55-e66.	1.1	89
39	Spectrum of movement disorders and neurotransmitter abnormalities in paediatric <i>POLG</i> disease. Journal of Inherited Metabolic Disease, 2018, 41, 1275-1283.	3.6	12
40	Postsynaptic movement disorders: clinical phenotypes, genotypes, and disease mechanisms. Journal of Inherited Metabolic Disease, 2018, 41, 1077-1091.	3.6	24
41	<i>GNAO1</i> encephalopathy. Neurology: Genetics, 2017, 3, e143.	1.9	84
42	Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN). Molecular Genetics and Metabolism, 2017, 120, 278-287.	1.1	64
43	Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia. Nature Genetics, 2017, 49, 223-237.	21.4	186
44	Not all <i>SCN1A</i> epileptic encephalopathies are Dravet syndrome. Neurology, 2017, 89, 1035-1042.	1.1	97
45	Utility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on Childhood Neurological Disorders. Frontiers in Molecular Neuroscience, 2016, 9, 78.	2.9	29
46	Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis. Journal of Medical Genetics, 2016, 53, 310-317.	3.2	191
47	Delineation of the movement disorders associated with <i>FOXP1</i> mutations. Neurology, 2016, 86, 1794-1800.	1.1	55
48	De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions. American Journal of Human Genetics, 2016, 98, 763-771.	6.2	96
49	Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. American Journal of Human Genetics, 2016, 98, 735-743.	6.2	65
50	Psychiatric disorders, myoclonus dystonia and <i>SGCE</i> : an international study. Annals of Clinical and Translational Neurology, 2016, 3, 4-11.	3.7	43
51	<i>GABRB3</i> mutations: a new and emerging cause of early infantile epileptic encephalopathy. Developmental Medicine and Child Neurology, 2016, 58, 416-420.	2.1	56
52	<i>RARS2</i> mutations in a sibship with infantile spasms. Epilepsia, 2016, 57, e97-e102.	5.1	23
53	Absence of the Autophagy Adaptor SQSTM1/p62 Causes Childhood-Onset Neurodegeneration with Ataxia, Dystonia, and Gaze Palsy. American Journal of Human Genetics, 2016, 99, 735-743.	6.2	99
54	The clinical syndrome of dystonia with anarthria/aphonia. Parkinsonism and Related Disorders, 2016, 24, 20-27.	2.2	10

#	ARTICLE	IF	CITATIONS
55	<i>L</i> YRM7 mutations cause a multifocal cavitating leukoencephalopathy with distinct MRI appearance. <i>Brain</i> , 2016, 139, 782-794.	7.6	51
56	The genetic landscape of the epileptic encephalopathies of infancy and childhood. <i>Lancet Neurology</i> , 2016, 15, 304-316.	10.2	474
57	The novel R347G pathogenic mutation of aromatic amino acid decarboxylase provides additional molecular insights into enzyme catalysis and deficiency. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2016, 1864, 676-682.	2.3	15
58	Faulty cardiac repolarization reserve in alternating hemiplegia of childhood broadens the phenotype. <i>Brain</i> , 2015, 138, 2859-2874.	7.6	30
59	Neurodegeneration with Brain Iron Accumulation: Genetic Diversity and Pathophysiological Mechanisms. <i>Annual Review of Genomics and Human Genetics</i> , 2015, 16, 257-279.	6.2	195
60	Monoamine neurotransmitter disorders—clinical advances and future perspectives. <i>Nature Reviews Neurology</i> , 2015, 11, 567-584.	10.1	221
61	The clinical and genetic heterogeneity of paroxysmal dyskinesias. <i>Brain</i> , 2015, 138, 3567-3580.	7.6	129
62	Benign Hereditary Chorea: An Update. <i>Tremor and Other Hyperkinetic Movements</i> , 2015, 5, 314.	2.0	30
63	Genetic disorders of thyroid metabolism and brain development. <i>Developmental Medicine and Child Neurology</i> , 2014, 56, 627-634.	2.1	19
64	Atypical <i>PLA2G6</i> -Associated Neurodegeneration: Social Communication Impairment, Dystonia and Response to Deep Brain Stimulation. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 128-131.	1.5	13
65	A type I interferon signature identifies bilateral striatal necrosis due to mutations in <i>ADAR1</i> . <i>Journal of Medical Genetics</i> , 2014, 51, 76-82.	3.2	118
66	Exome Sequence Reveals Mutations in CoA Synthase as a Cause of Neurodegeneration with Brain Iron Accumulation. <i>American Journal of Human Genetics</i> , 2014, 94, 11-22.	6.2	176
67	Severe infantile epileptic encephalopathy due to mutations in <i>PLCB1</i> : expansion of the genotypic and phenotypic disease spectrum. <i>Developmental Medicine and Child Neurology</i> , 2014, 56, 1124-1128.	2.1	21
68	What is new for monoamine neurotransmitter disorders?. <i>Journal of Inherited Metabolic Disease</i> , 2014, 37, 619-626.	3.6	40
69	Pantothenate Kinase-Associated Neurodegeneration (PKAN) and <i>PLA2G6</i> -Associated Neurodegeneration (PLAN). <i>International Review of Neurobiology</i> , 2013, 110, 49-71.	2.0	68
70	Beta-propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. <i>Brain</i> , 2013, 136, 1708-1717.	7.6	203
71	Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrum. <i>Brain</i> , 2013, 136, 1578-1591.	7.6	144
72	Exome Sequencing Reveals De Novo <i>WDR45</i> Mutations Causing a Phenotypically Distinct, X-Linked Dominant Form of NBIA. <i>American Journal of Human Genetics</i> , 2012, 91, 1144-1149.	6.2	309

#	ARTICLE	IF	CITATIONS
73	Niemannâ€Pick type C disease as proofâ€ofâ€concept for intelligent biomarker panel selection in neurometabolic disorders. <i>Developmental Medicine and Child Neurology</i> , 0, , .	2.1	6